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Background. Chronic kidney disease (CKD) has been linked
to higher stroke risk. Anemia is a common consequence of
CKD, and recent evidence suggests anemia may increase risk
of cardiovascular events. The combined effect of CKD and
anemia on stroke risk, however, has not been investigated
thoroughly. We analyzed data from a middle-aged, community-
based cohort to determine if CKD and anemia interacted to
affect stroke risk.
Methods. Data on 13,716 participants in the prospective
Atherosclerosis Risk in Communities (ARIC) Study were ana-
lyzed to assess the joint effect of CKD and anemia on risk of
incident stroke during a 9-year follow-up period. CKD was
defined as a creatinine clearance of 60 mL/min. Anemia was
defined as hemoglobin levels of13 g/dL for men or12 g/dL
for women.
Results. Overall, CKD was associated with an increase in
stroke risk after adjustment for other factors [hazard ratio
HR) 1.81; 95% CI 1.26 to 2.02]. However, this association was
modified substantially by anemia. In the presence of anemia,
CKD was associated with a substantially higher risk of stroke
compared to no CKD (HR 5.43; 95% CI 2.04 to 14.41). In
contrast, when anemia was not present, CKD was associated
with only a modest, nonsignificant elevation in stroke risk (HR
1.41; 95% CI 0.93 to 2.14). The interaction between CKD and
anemia on risk of stroke was statistically significant (P 0.01).
Conclusion. Among middle-aged, community-based per-
sons, the combination of CKD and anemia was associated
with a substantial increase in stroke risk, independent of other
known risk factors for stroke.
Several reports have indicated that chronic kidney dis-
ease (CKD) is associated with a higher risk of stroke
[1–4]. This association has been observed after adjust-
ment for a variety of factors, including comorbid condi-
tions such as hypertension and diabetes. Anemia is a
common condition among persons with CKD [5]. Recent
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evidence suggests that anemia may be an independent
predictor of adverse cardiovascular events [6].
Given the evidence noted above, one might suspect
that the association between CKD and increased stroke
risk could be especially strong when CKD is accompa-
nied by anemia. Knowledge of whether such an interac-
tion exists with respect to stroke would be important in
risk-stratifying persons for the development of stroke.
However, we were unaware of any large scale, commu-
nity-based, epidemiologic investigations that have exam-
ined whether moderate CKD interacts with anemia to
affect stroke risk. Accordingly, the present study exam-
ined the joint effect of CKD and anemia on the risk of
incident stroke in a large, prospective cohort study of a
middle-aged, community-based population.
METHODS
Study population
The Atherosclerosis Risk in Communities Study (ARIC)
was a prospective cohort study of risk factors for cardio-
vascular disease in a middle-aged, community-based popu-
lation [7]. Recruitment of the cohort and baseline data
collection took place from 1987 to 1989. During that
time, ARIC investigators recruited 15,792 participants
from four communities in the United States: Jackson,
Mississippi; Forsyth County, North Carolina; Washing-
ton County, Maryland; and select suburbs of Minneapolis,
Minnesota. Participants were initially contacted through
the mail and then interviewed by ARIC investigators. All
of the participants from Jackson were African American,
and African Americans were oversampled in Forsyth
County, North Carolina. Virtually all participants from
Minneapolis and Washington County, Maryland were
Caucasians. At baseline, all participants were between
the ages of 45 and 64 years. For the present study, we
excluded ARIC participants who had a self-reported his-
tory of stroke at baseline, as well as participants who
had missing data on renal function, anemia, or other co-
variates of interest. After all exclusions, the sample size
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for the present study was reduced to 13,716. The study
was approved by an Institutional Review Board and all
subjects gave informed consent.
Ascertainment of chronic kidney disease and anemia
At baseline, each participant was asked to fast for 12
hours and then undergo a physical examination in which
blood samples were collected. From these samples, inves-
tigators measured serum creatinine with a DACOS Ana-
lyzer (Coulter Diagnostics, Hialeah, FL, USA) using a
modified kinetic Jaffe method. In the present study, we
used each participant’s baseline serum creatinine level,
baseline body weight (measured by a calibrated scale),
and gender to calculate estimated baseline creatinine
clearance according to the Cockroft-Gault formula [8].
This estimate of creatinine clearance was regarded as
an indicator of a participant’s baseline renal function.
Creatinine clearance was dichotomized at 60 mL/min
versus60 mL/min, a cut point that has been previously
suggested to distinguish moderate CKD (creatinine
clearance 60 mL/min) from better renal function (cre-
atinine clearance 60 mL/min) [9].
Baseline blood samples were also used to measure
each participant’s hemoglobin level. At the Jackson, Mis-
sissippi and Washington County, Maryland sites, a Coulter
S IV instrument (Coulter Diagnostics) was used to mea-
sure hemoglobin levels from the blood samples. At the
Minneapolis, Minnesota site, hemoglobin levels were
measured using Coulter S III and Coulter S IV instru-
ments. In Forsyth County, North Carolina, a Technicon
H-6000 instrument (Technicon Corporation, Tarrytown,
NY, USA) was used to measure hemoglobin. Consistent
with the World Health Organization definition of ane-
mia, we classified ARIC participants as anemic if their
hemoglobin level was 13 g/dL (men) or 12 g/dL
(women) [10]. Further details on the handling of blood
specimens and the measurement of creatinine and hemo-
globin in ARIC have been published elsewhere [11, 12].
Ascertainment of other explanatory variables
In addition to baseline CKD and anemia, other explan-
atory variables were measured at baseline that could
be predictive of stroke. These variables included age,
gender, race, and education as determined from ques-
tionnaires; prevalent coronary heart disease, defined as
a history of myocardial infarction or cardiac revasculari-
zation procedures; diabetes, defined as serum fasting glu-
cose 126 mg/dL, self-reported physician diagnosis of
diabetes, or use of oral hypoglycemic agents; insulin lev-
els determined by a nonspecific radioimmunoassay; sys-
tolic and diastolic blood pressure determined from the
average of the second and third measurements made by
a trained technician using a random zero sphygmoma-
nometer; high-density lipoprotein (HDL) cholesterol de-
termined by using enzymatic methods and low-density
lipoprotein (LDL) cholesterol calculated using the Frie-
denwald equation; carotid intimal media thickness deter-
mined by B-mode ultrasonography; and current smok-
ing, as determined by a standardized questionnaire. Ex-
planatory variables that were considered as categoric
variables in analyses were gender, race (African Ameri-
can vs. non-African American), education (12 years,
12 years, 12 years), prevalent coronary heart disease
(yes vs. no), diabetes (yes vs. no), and current smoking
(yes vs. no). All other explanatory variables were treated
as continuous.
Ascertainment of stroke outcome
The outcome of interest in this study was the occur-
rence of a hospitalized nonfatal or fatal stroke. All parti-
cipants were followed-up from baseline until December
31, 1995 for the occurrence of stroke events. ARIC per-
sonnel identified potential strokes by making annual tele-
phone calls to study participants and by conducting mor-
bidity and mortality surveillance in local hospitals. When
a participant was identified as having had a potential
stroke, trained abstractors recorded relevant informa-
tion on symptoms and signs from medical records and
hospital discharge summaries. Relevant information in-
cluded timing, type, and duration of neurologic symp-
toms and deficits (e.g., headache, vertigo, aphasia, con-
vulsions, paralysis), medical history, the results of the
procedures performed [catheterization, heart surgery,
cerebral angiography, carotid endarterectomy, computed
tomography (CT) or magnetic resonance imaging (MRI)
scan, ultrasound, lumbar puncture], anticoagulant or
thrombolytic therapy, and autopsy evidence. Based on
this information and on criteria adopted by the National
Survey of Stroke [13], potential events were subjected
to a computer algorithm and physician review in order
to classify the event as a definite stroke, probable stroke,
possible stroke, or not a stroke. Only those events that
were classified as definite or probable strokes were counted
as stroke events in the current study. The minimum crite-
ria for a definite or probable stroke was evidence of
rapid or sudden onset of neurologic symptoms consistent
with stroke lasting for 24 hours or leading to death, in
the absence of evidence for a nonstroke cause. Addi-
tional details on stroke surveillance and classification in
ARIC have been published elsewhere [14].
Statistical analysis
The goal of our analyses was to determine if CKD, as
indicated by a creatinine clearance of 60 mL/min, was
associated with stroke risk and whether this association
was modified by anemia. As a first step in our analysis,
we compared creatinine clearance groups with respect
to the prevalence of anemia and the distribution of other
baseline characteristics. We then compared crude stroke
incident rates according to creatinine clearance level.
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Table 1. Distribution of study characteristics in the entire group and according to creatinine clearance categories
Creatinine clearance Creatinine clearance P value for difference
Entire sample 60 mL/min 60 mL/min between creatinine
Characteristic (N  13,716) (N  11,626) (N  2090) clearance groups
Serum creatinine mg/dL (mean) 1.100.34 1.080.18 1.220.75 0.01
Hemoglobin mean 13.91.10 14.01.41 13.41.34 0.01
Anemia % 9.2 8.7 12.2 0.01
Age years (mean) 54.15.7 53.65.6 57.35.5 0.01
Male % 44.7 49.0 20.8 0.01
African American % 24.8 25.7 20.0 0.01
Education 12 years % 22.9 22.8 23.3 0.60
Prevalent coronary heart disease % 4.5 4.3 5.2 0.08
Prevalent diabetes % 10.6 11.0 8.0 0.01
Insulin lu/mL (mean) 13.527.6 14.026.3 11.133.4 0.01
Systolic blood pressure mm Hg (mean) 120.718.6 120.918.2 119.820.8 0.02
Diastolic blood pressure mm Hg (mean) 73.411.2 73.911.1 70.811.5 0.01
Antihypertensive medication use % 23.7 23.5 24.6 0.25
Low-density lipoprotein cholesterol
mg/dL (mean) 137.339.1 137.638.8 136.141.2 0.12
High-density lipoprotein cholesterol
mg/dL (mean) 52.117.0 50.716.2 60.219.0 0.01
Body mass index kg/m2 (mean) 27.55.1 28.25.0 23.13.2 0.01
Carotid intima medial thickness mm (mean) 0.720.20 0.720.20 0.730.21 0.04
Current smoking % 25.9 25.3 28.7 0.01
Means includeSD. P values for the association between creatinine clearance categories and categorical study characteristics were calculated based on the chi-
square test. P values for the association between creatinine clearance categories and continuous study characteristics were calculated based on the t test.
This comparison of crude rates was made in the entire
sample and within the anemic and nonanemic subgroups.
To assess whether the dichotomous creatinine clearance
variable was predictive of stroke after adjustment for other
variables, we ran a multivariable adjusted Cox propor-
tional hazards model. The dichotomous creatinine clear-
ance variable, the dichotomous hemoglobin variable, and
all of the other explanatory variables described earlier
were entered into the model as independent variables,
and time to first stroke was entered as the outcome. To
see if the association between creatinine clearance and
stroke from this model was dependent upon anemia sta-
tus, we reran the model by adding in a cross-product term
representing the interaction between the dichotomous
creatinine clearance and dichotomous anemia variables.
If the model revealed that the interaction term was statis-
tically significant (P  0.05), we then ran separate Cox
models for the anemic and nonanemic subgroups in or-
der to assess the multivariable adjusted association be-
tween creatinine clearance and stroke within each ane-
mia subgroup. All P values reported in this study were
two sided, and all statistical analyses were conducted
using Statistical Analysis Software version 8.2 (SAS In-
stitute, Cary, NC, USA).
RESULTS
The mean age of the 13,716 participants included in
our study was 54.1 years, with 44.7% of participants
being male and 24.8% were African Americans. Approx-
imately 15.2% of the sample had a creatinine clearance
of 60 mL/min. The distribution of anemia and other
variables according to creatinine clearance is shown in
Table 1. Compared to persons with a creatinine clearance
60 mL/min, those with a creatinine clearance 60 mL/
min were more likely to be anemic, older, female, Cauca-
sian, nondiabetic, and current smokers. Persons with a
creatinine clearance 60 mL/min also had higher mean
values for serum creatinine and HDL cholesterol, and
lower mean values for hemoglobin, insulin, and diastolic
blood pressure. Education levels, mean LDL cholesterol
values, prevalent coronary heart disease, and mean ca-
rotid intimal media thickness did not appear to vary
substantially with creatinine clearance.
In the entire sample, a lower creatinine clearance was
associated with a higher crude stroke rate (Fig. 1). Among
those with a creatinine clearance of 60 mL/min, the
crude stroke rate per 100 person-years of follow-up was
3.70 (54 events during 14,594 person-years), while among
those with a creatinine clearance 60 mL/min, the rate
was 2.06 (171 events during 83,001 person-years) [crude
rate ratio (RR)] for low vs. high creatinine clearance 
1.80; P 0.01). The association between lower creatinine
clearance and higher stroke rates was stronger in the
subgroup of persons with anemia (Fig. 1). Among those
with anemia, the crude stroke rates per 1000 person-
years for those in the60 mL/min and60 mL/min and
creatinine clearance groups were 10.53 (17 events during
1615 persons years) and 1.52 (10 events during 6953
persons years), respectively (crude RR 6.92; P 0.01).
In the subgroup without anemia, the difference in crude
stroke rates was modest. For those with a low creatinine
clearance, the rate was 2.85 (37 events during 12,979
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Fig. 1. Stroke rates per 1000 person-years of follow-up according to
creatinine clearance, in the entire sample, and stratified according to
anemia status.
person-years) and for those with a high creatinine clear-
ance, the rate was 2.12 (161 events during 76,049 person
years) (crude RR  1.34; P  0.05).
We next ran a Cox proportional hazards model, which
assessed whether the dichotomous creatinine clearance
variable was a predictor of time to stroke after adjust-
ment for the dichotomous anemia variable and all of
the other explanatory variables (Table 2). The model
showed that a low creatinine clearance was associated
with a statistically significant increase in the risk of
stroke, independently of other risk factors [hazard ratio
(HR)] 1.81; 95% CI 1.26 to 2.02; P 0.01). To see if this
association was modified by (interacted with) anemia, we
reran this model by adding in a creatinine clearance 
anemia interaction term. The interaction term proved
to be statistically significant (P  0.01). We therefore
ran separate multivariable adjusted models in the anemic
and nonanemic subgroups to examine how the associa-
tion between creatinine clearance and stroke risk varied
according to anemia status. Low creatinine clearance
was associated with a substantially elevated risk of stroke
in the anemic group after adjustment for other risk fac-
tors (HR 5.43; 95% CI 2.05 to 14.41; P  0.01), but was
associated with only a modest increase in stroke risk in
the normal hemoglobin group (HR 1.41; 95% CI 0.93
to 2.14; P  0.10) (Table 2).
We then conducted a number of secondary analyses.
First, we considered whether the strong association be-
tween low creatinine clearance and stroke risk in anemic
persons differed according to stroke subtype. When the
outcome was restricted to ischemic stroke (187 events),
a creatinine clearance of 60 mL/min was indeed a
strong and significant predictor of ischemic stroke in
persons with anemia (adjusted HR 10.34; 95% CI 1.00
to 29.00; P  0.03), but was not associated with ischemic
stroke risk in nonanemic persons. Unfortunately, a simi-
lar analysis was not possible for hemorrhagic stroke be-
cause there were too few hemorrhagic stroke outcomes
(22 events) to conduct this analysis with sufficient preci-
sion. Second, we examined whether our main results
were similar when calculating creatinine clearance ac-
cording to the abbreviated Modified Diet in Renal Dis-
ease (MDRD) [9] equation instead of the Cockroft-
Gault formula. We found that calculation of creatinine
clearance according to the MDRD formula did little to
affect our main results. An MDRD-calculated creatinine
clearance of 60 mL/min was associated with a substan-
tially higher risk of stroke among anemic persons (HR
5.80; 95% CI 2.26 to 14.80; P  0.01), but not among
nonanemic persons (HR 1.24; 95% CI 0.88 to 1.75; P 
0.23) (P  0.01 for the interaction between MDRD-
calculated creatinine clearance and anemia). Third, we
considered modeling an interaction between continuous
creatinine clearance and continuous hemoglobin. When
we ran such a model however, we found that creatinine
clearance and hemoglobin did not significantly interact
to affect stroke risk. This suggested that creatinine clear-
ance and hemoglobin tended to interact more strongly
at the cut points used in our main analyses. Finally, we
reran our models after excluding persons with a creati-
nine clearance of15 mL/min, and found that our results
were virtually unchanged.
DISCUSSION
In the present study, we found that CKD, as indicated
by a creatinine clearance of60 mL/min, was associated
with an increased risk of stroke in a middle-aged, com-
munity-based population, independently of demograph-
ics, blood pressure, lipids, smoking, and other known
factors that can predict stroke. However, we found that
this association depended upon the presence of anemia.
In those with anemia, CKD was associated with an espe-
cially marked increase in stroke risk, while in those with-
out anemia, CKD was associated with only a modest
increase in the risk of stroke. Prior investigations have
reported that CKD is associated with higher stroke risk
in persons with isolated systolic hypertension [2, 4] and
others populations [1, 3], and there is recent evidence
that anemia is an independent risk factor for cardiovas-
cular disease [6]. Additionally, investigators have dem-
onstrated that CKD may interact with anemia to increase
the risk of all-cause mortality in persons with left ventric-
ular hypertrophy [15]. To the best of our knowledge
however, our study is the first to examine how moderate
CKD and anemia interact to affect the risk of incident
stroke among community-based persons.
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Table 2. Results of adjusted Cox regression models assessing creatinine clearance as a predictor of stroke in the entire sample and stratified
according to anemia status
Total sample Anemic group Nonanemic group
Adjusted Adjusted Adjusted
relative riska 95% CI relative riska 95% CI relative riska 95% CI
Creatinine clearance 60 mL/min 1.00 Referent 1.00 Referent 1.00 Referent
Creatinine clearance 60 mL/min 1.81 1.26–2.02 5.43 2.04–14.41 1.41 0.93–2.14
aAdjusted for age, gender, race, prevalent coronary heart disease and diabetes, insulin, systolic and diastolic blood pressure, antihypertensive medication use, low-
density lipoprotein and high-density lipoprotein cholesterol, body mass index, current smoking, and carotid intima medial thickness.
The reasons for the substantially higher risk of stroke
among persons with CKD and anemia are not entirely
clear. CKD may induce pathophysiologic processes, which
may increase stroke risk, and anemia simply may be a
marker of the duration and/or severity of CKD. For
example, accumulating evidence indicates that CKD could
induce oxidative stress [16] and oxidative stress, in turn,
could promote atherosclerosis [17, 18]. Indeed, a recent
investigation linked oxidative stress with carotid plaques
[19]. Atherosclerosis, in turn, could potentially promote
cerebral ischemia and increase the risk of ischemic stroke.
Additionally, CKD appears to promote left ventricular
hypertrophy [20], which has been shown to be a strong
predictor of stroke risk. [21] Thus, by inducing athero-
sclerosis and left ventricular hypertrophy, CKD may
have direct, pathosphysiologic effects that increase stroke
risk. Since anemia often develops as a consequence of
CKD, one could simply regard anemia as a proxy for the
duration and severity of CKD and its stroke-promoting
pathophysiologic effects. Under such a scenario, the high
stroke rate in those with CKD and anemia would not
indicate that the two conditions each have their own effects
that interact to elevate stroke risk. Instead, it would simply
indicate that stroke risk is determined by the duration
and severity of CKD. We cannot rule out this scenario
as a potential explanation for our results, because we
did not have information on the duration of CKD.
Alternatively, it may be that CKD and anemia each
have independent pathways through which they lead to
stroke, and that when the two conditions are present
together, they truly interact to substantially elevate
stroke risk. As already noted, CKD might increase stroke
risk promoting ischemia and left ventricular hypertro-
phy. There is evidence that anemia is associated with
myocardial ischemia [22–24], although it is not known
whether anemia also facilitates cerebral ischemia. In the
heart, pathophysiologic adaptations associated with ane-
mia can lead to left ventricular hypertrophy in the long-
term, especially when they take place in the presence of
CKD [5]. Thus, the co-occurrence of CKD and anemia
may result in an environment that is especially capable
of promoting ischemia and left ventricular hypertrophy,
and this could explain why we observed a dramatically
higher stroke risk in the group with CKD and anemia.
Another possible mechanism that could account for an
interaction between CKD and anemia or stroke risk con-
cerns erythropoietin. The potential for anemia to ad-
versely affect the brain could be counteracted by in-
creased production of erythropoietin, which appears to
have neuronal protective effects in animal models of
ischemia-induced stroke and brain injury [25–28]. How-
ever, when renal function is reduced, the ability of the
kidneys to produce erythropoietin is impaired, which
could potentially limit erythropoietin-induced neuronal
protection against anemia-induced strokes. In this way,
the combination of anemia and reduced kidney function
could interact to make a stroke event more likely to
occur or more likely to be clinically severe. We had no
information on erythropoietin in this study, so such an
explanation remains speculative.
This study had a number of limitations. First, it was
based on observational data and we cannot rule out
confounding factors as an explanation for our results.
Inflammation, for example, may underlie both CKD and
anemia [29, 30], and inflammation has also been reported
to increase stroke risk [31]. Thus, a combination of CKD
and anemia may be associated with higher stroke risk,
not because they are causal factors in the development
of stroke, but simply because they are associated with
inflammatory processes that increase stroke risk. Second,
our measure of CKD was only based on estimated creati-
nine clearance and not on measured glomerular filtration
rate (GFR). This may have led to some misclassification
of CKD status, although it would seem such misclassifi-
cation would probably have been nondifferential and
would, therefore, have biased our results toward the null.
Third, there is a possibility that investigators failed to
identify “subclinical” strokes, which could have led to
misclassification of the stroke outcome in this study.
Again, however, it seems probable that this potential
misclassification would have been nondifferential, which
would have led to an underestimate of the interaction
between CKD and anemia on stroke risk. Fourth, be-
cause there were only a moderate number of stroke
events in our study, it was difficult to examine precisely
whether the interaction between CKD and anemia was
more or less pronounced for particular stroke subtypes,
such as ischemic or hemorrhagic stroke. We did examine
the interaction between CKD and anemia on risk of
ischemic stroke and found that the interaction was very
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strong. However, we were unable to assess with any
precision this interaction was specific to ischemic stroke
or whether it also involved hemorrhagic stroke. The
small number of events also precluded us from conduct-
ing other analyses, which may have been of interest, such
as separate analyses in African Americans and Cauca-
sians and in those with and without prevalent coronary
heart disease at baseline, or analyses using more than
two cut points for CKD and anemia in order to examine
dose-response effects. Fifth, we had no information on
the duration of CKD or anemia in our data, and so we
could not incorporate this information in to our analyses.
CONCLUSION
Our study indicates that CKD is associated with an
increased risk of stroke among community-based, mid-
dle-aged persons, and that this increased risk is especially
high in persons who also have anemia. The sheer magni-
tude of the interaction we found between CKD and
anemia was quite notable. The reasons for this finding
are not clear. Nevertheless, our results indicate that com-
munity-based persons with CKD and anemia may war-
rant special attention with respect to stroke risk. If our
results are confirmed, they could aid in risk-stratifying
community-based populations for the development of
stroke.
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